HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

P&G finalizes Clairol assimilation plans

This article was originally published in The Rose Sheet

Executive Summary

Manufacturing consolidation of Clairol will be completed by fall 2003, P&G says. Company will maintain Clairol hair color manufacturing operations in Stamford, Conn., Vallejo, Mexico and Sydney, Australia. Hair care manufacturing will be consolidated at existing P&G plants globally, and company will close Clairol facilities in Peru, Venezuela, the UK and New Jersey. Continuing employment opportunities will exist for 800 of current 1,550 manufacturing employees. P&G announced integration of non-manufacturing business in January (1"The Rose Sheet" Jan. 28, 2002, In Brief)...

You may also be interested in...



P&G cuts Clairol jobs

Procter & Gamble will cut more than 1,400 Clairol jobs as part of phase one of its business integration, company announces Jan. 22. First-phase cuts will be non-manufacturing positions, primarily from Clairol's Stamford, Conn. headquarters and international locations. Of approximately 710 non-manufacturing jobs in Stamford, Conn., about 250 positions will be maintained. Internationally, P&G will make 815 reductions. P&G previously announced Clairol color/professional will be based in Stamford, while hair care/personal care will be integrated with P&G's beauty businesses ("The Rose Sheet" Nov. 19, 2001, In Brief). A second phase, covering manufacturing integration, will be finalized in March...

Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round

Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.

Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children

Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS010109

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel